ebola

Leaving trash in the streets was a bad move, Anne Arundel County government.

The Johns Hopkins Medicine biocontainment unit is one of 10 regional centers across the country prepared to provide treatment in the event of an infectious disease or bioterrorism attack.

If lawmakers in Washington truly seek to strengthen America against all threats foreign or domestic, they must reauthorize the Pandemic and All-Hazards Preparedness Act. Isolationism is not an option with infectious diseases, and PAHPRA keeps the United States engaged and vigilant.

Two Baltimore firms will work to develop and manufacture a vaccine for the Lassa virus, a deadly emerging virus threat in Africa, under a $36 million grant from a global disease preparedness organization.

“This is a serious flu, but it is actually a typical H3N2 epidemic,” Taylor said, noting the particular strain of the flu virus predominate at the moment. “Flu every year kills people.”

The wave of monument removal throughout America is a symptom of an old Western disease: victimization and resentment, says Jonah Goldberg.

Tulane University scientists will get $12 million for animal studies to test drug combinations.

President Donald Trump's budget would leave the U.S. more vulnerable to global health security threats, according to Johns Hopkins faculty.

When the next flu pandemic strikes, a newly expanded pharmaceutical plant in East Baltimore now stands ready to respond. Emergent BioSolutions, in partnership with the federal government, spent $80 million to double the size of its East Lombard Street plant near Johns Hopkins Bayview Medical Center.

An ecology graduate from the University of Delaware and former Peace Corps volunteer has beaten hundreds of competitors from around the world to a $12,500

Federal approval for a new drug can take a decade or more, but researchers at Johns Hopkins University are studying a way to shave off years for medications meant for serious outbreaks of flu, Ebola or other infectious disease

The $1.1 billion allocated by Congress last week to target Zika will mean more money for states and localities to control and monitor for the mosquito-borne virus and for researchers to development of vaccines and diagnostic tests

Zika vaccine developed by Emergent headed for clinical trials.

With an official link established this week by the U.S. Centers for Disease Control and Prevention between Zika and birth defects, and warmer weather expected to propel the mosquito-borne virus north, the push is intensifying for a drug to prevent or treat infections

The appearance of Zika in Maryland represents a public health threat that could affect the entire Mid-Atlantic region

Almost a year after deploying to Liberia to help fight Ebola, soldiers with the 1st Area Medical Laboratory are still combing over the experience, looking to share tips that might help the Army better respond to major disease outbreaks in future.

A dangerous new pathogen

Baltimore biotechnology company Profectus BioSciences is testing a vaccine to guard against the Ebola virus on 39 human subjects, a first step toward administering it more broadly in people at risk of exposure to the deadly pathogen.

Looking back at new developments in health, science, and technology this year, one thing is clear — 2015 was a banner year for medical milestones, scientific breakthroughs and technological advances at local universities and biotech companies.

A single vaccine Profectus BioSciences is developing to protect against two strains of the Ebola virus and a third similar pathogen is effective in monkeys.

Two Baltimore institutions will share in $11 million in new funding from the U.S. Center for Disease Control and Prevention aimed at preventing the spread of germs, which continues to be both a deadly and costly problem in health care settings.

A suit developed by a group from the Johns Hopkins University will soon be available to protect people on the front lines of the Ebola crisis.

Middle East Respiratory Syndrome, or MERS, is similar to another deadly coronavirus identified a decade ago called Severe Acute Respiratory Syndrome, giving scientists a jump on the investigation into their origins.

Novavax Inc.'s Ebola vaccine helped healthy people develop an immune response against the deadly virus in an early trial.

Gaithersburg biotechnology company Emergent BioSolutions will make a treatment for the Ebola virus at its East Baltimore manufacturing facility, the company said Monday.

A research partnership between U.S. and Liberian health officials has launched a study to learn more about the long-term health consequences of Ebola, including why it commonly causes vision damage and eye inflammation.

The Baltimore City Health Department said Monday that a traveler who returned from West Africa recently with a fever does not have Ebola.

A person who had recently returned from West Africa was admitted Sunday to Johns Hopkins Hospital, complaining of a fever, city health officials said.

The U.S. Army Edgewood Chemical Biological Center and the U.S. Army Medical Research Institute of Infectious Diseases are partnering to help expedite progress in the global fight against Ebola. ECBC is working with USAMRIID on two critical studies –a vaccine study and a biomarker study – that will advance the global fight against Ebola.

Early in the morning of Sunday, May 17, thousands of athletes will descend on Centennial Park in Ellicott City. We talked to three local competitors about the inspiring stories that led them to swim, bike and run.

With the current momentum to do more to facilitate the detection and response to viral infections, we encourage national and global public policy makers, business leaders and academic leaders to increase support for the training of the next generation of medical virologists as part of comprehensive pandemic preparedness plans.

Research being published Thursday suggests that an Ebola vaccine being developed by Baltimore company Profectus BioSciences is effective against the strain of the virus that has ravaged West Africa, a milestone the company says is a first in the race to prevent future Ebola outbreaks.

An American health worker being treated for Ebola at the National Institutes of Health's Clinical Center in Bethesda has been upgraded from fair to good condition, the NIH said Tuesday.

Johns Hopkins Hospital has built a unit designed to safely care for patients with Ebola and other dangerous pathogens, joining only a handful of institutions with such facilities in the country.

Maryland residents who have been to any of the three West African countries battling an Ebola outbreak now can use their smartphone or computer to report possible symptoms to the state health department, the agency and the application's developer said Wednesday.

Twenty-two members of a mobile Army medical laboratory are returning to Aberdeen Proving Ground after four months fighting Ebola in West Africa.

At its growing East Baltimore facility, Emergent BioSolutions has produced a booster shot to go with a leading Ebola vaccine candidate, joining in a competitive race to make a safe and effective tool to stop the spread of an outbreak that continues in West Africa and to prevent future outbreaks.

An American health worker who contracted the Ebola virus in Sierra Leone is in critical condition at the National Institutes of Health Clinical Center in Bethesda, officials said Monday.

A health worker who contracted the Ebola virus while volunteering in Sierra Leone was admitted to the National Institutes of Health Clinical Center in Bethesda on Friday, NIH officials said.

A U.S. military medical unit from Aberdeen Proving Ground in Maryland is packing up four mobile Ebola testing laboratories in Liberia after a nearly four-month deployment.

Four Web-based training videos developed by Johns Hopkins Medicine and others aim to train doctors, nurses and other medical professionals in the proper way to handle patients who show up at their hospitals with serious infectious diseases.

Carroll County and Maryland on the whole are well-vaccinated against measles, but officials say to take nothing for granted

The spike in homicides in Baltimore's Northeast district resembles the spread of an infectious disease; is there an effective 'vaccine' to fight the epidemic?

The state has launched a new website to help corral donations for areas in West Africa afflicted by the Ebola virus.

To beat Ebola as we've overcome other global epidemics, officials must preserve access to animal research. Cures for this deadly pathogen — and thousands of lives — depend on it.

Thousands of people are to be injected with two experimental Ebola vaccines in trials in West Africa within a couple of weeks, and a Baltimore biotechnology company is launching a human trial of its own candidate in June, as scientists and public health officials work to end the deadly epidemic.

Mutations to the Ebola virus could make some experimental treatments ineffective, according to researchers at Fort Detrick.

As I work with dozens of donors and partners on the Ebola frontlines in Liberia, it's difficult to accept news reports of rampant disorganization, poor planning and infighting. These dispatches may reflect the initial challenges of pooling our resources in the most productive ways, but they have not told the entire story of the work taking place in Liberia in the battle against Ebola. My colleagues and I are working in harmony with one another and with Liberia's Ministry of Health. What's more,